Efficacy and Safety of XM22 compared to pegfilgrastim in patients with breast cancer receiving chemotherapy. A multinational, multicentre, randomised, double-blind controlled study

Trial Profile

Efficacy and Safety of XM22 compared to pegfilgrastim in patients with breast cancer receiving chemotherapy. A multinational, multicentre, randomised, double-blind controlled study

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2015

At a glance

  • Drugs Lipegfilgrastim (Primary) ; Pegfilgrastim
  • Indications Neutropenia
  • Focus Pharmacogenomic; Pharmacokinetics; Therapeutic Use
  • Sponsors BioGeneriX
  • Most Recent Events

    • 20 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top